ORCID
Kazuyo Kuzume: 0000-0001-5880-5678
Kenji Matsumoto: 0 000-0002-2630-6927
References
  1. Nair P, Martin JG, Cockcroft DC, Dolovich M, Lemiere C, Boulet LP, et al. Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. J Allergy Clin Immunol Pract. 2017;5:649-659.
  2. Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma.Immunity . 2019; 50:975-991.
  3. Ayakannu R, Abdullah NA, Radhakrishnan AK, Lechimi Raj V, et al. Relationship between various cytokines implicated in asthma. Hum Immunol. 2019;80:755-763.
  4. André-Grégoire G, Dilasser F, Chesné J, Braza F, Magnan A, Loirand G, et al. Targeting of Rac1 prevents bronchoconstriction and airway hyperresponsiveness. J Allergy Clin Immunol. 2018;142:824-833.
  5. Manson ML, Säfholm J, James A, Johnsson AK, Bergman P, Al-Ameri M, et al. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145:808-817.
  6. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma.Am J Respir Crit Care Med. 2019;199:433-445.
  7. Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.Ther Adv Respir Dis. 2018;12:1753466618810192.
  8. Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-593.
  9. Makino S, Ikemori R, Fukuda T, Motojima S, Namai S, Toda M, et al. Clinical evaluation of standard method of acetylcholine inhalation test in bronchial asthma. Arerugi. 1984;33:167-175 (in Japanese).